Biomet Spinal Business Expansion Backs 15% Stock Gain In February
This article was originally published in The Gray Sheet
Executive SummaryBiomet's rapidly expanding spinal business and accelerating reconstructive device revenues, coupled with a history of predictable earnings growth, helped the firm's stock advance 15.2% during a generally chilly February for device issues. The stock closed the month at $38.81, a gain of $5.12.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.